Vaccine-elicited and naturally elicited antibodies differ in their recognition of the HIV-1 fusion peptide

Front Immunol. 2024 Nov 14:15:1484029. doi: 10.3389/fimmu.2024.1484029. eCollection 2024.

Abstract

Broadly neutralizing antibodies have been proposed as templates for HIV-1 vaccine design, but it has been unclear how similar vaccine-elicited antibodies are to their naturally elicited templates. To provide insight, here we compare the recognition of naturally elicited and vaccine-elicited antibodies targeting the HIV-1 fusion peptide, which comprises envelope (Env) residues 512-526, with the most common sequence being AVGIGAVFLGFLGAA. Naturally elicited antibodies bound peptides with substitutions to negatively charged amino acids at residue positions 517-520 substantially better than the most common sequence, despite these substitutions rarely appearing in HIV-1; by contrast, vaccine-elicited antibodies were less tolerant of sequence variation, with no substitution of residues 512-516 showing increased binding. Molecular dynamics analysis and cryo-EM structural analysis of the naturally elicited ACS202 antibody in complex with the HIV-1 Env trimer with an alanine 517 to glutamine substitution suggested enhanced binding to result from electrostatic interactions with positively charged antibody residues. Overall, vaccine-elicited antibodies appeared to be more fully optimized to bind the most common fusion peptide sequence, perhaps reflecting the immunization with fusion peptide of the vaccine-elicited antibodies.

Keywords: HIV-1 vaccine; fusion peptide; naturally elicited; neutralizing antibody; vaccine elicited.

MeSH terms

  • AIDS Vaccines* / immunology
  • Amino Acid Sequence
  • Antibodies, Neutralizing* / immunology
  • HIV Antibodies* / immunology
  • HIV Envelope Protein gp41 / chemistry
  • HIV Envelope Protein gp41 / immunology
  • HIV Infections* / immunology
  • HIV Infections* / virology
  • HIV-1* / immunology
  • Humans
  • Molecular Dynamics Simulation
  • Protein Binding
  • env Gene Products, Human Immunodeficiency Virus / chemistry
  • env Gene Products, Human Immunodeficiency Virus / immunology

Substances

  • AIDS Vaccines
  • HIV Antibodies
  • Antibodies, Neutralizing
  • env Gene Products, Human Immunodeficiency Virus
  • HIV Envelope Protein gp41

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Funding was provided by the Vaccine Research Center (VRC), an intramural Division of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), USA.